Overview

Thalidomide-Dexamethasone for Multiple Myeloma

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Thalidomide